Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Page, MD
Providence Health & Services
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ellison Institute of Technology (eitm)
Los Angeles, California, United States
Recruiting - Providence Portland Cancer Institute - Franz Clinic
Portland, Oregon, United States
Alison Conlin, MDAmy Hartman, NPEvelyn Brosnan, MDEvie Hobbs, MDKathleen Dronkowski, NPKimberlie Dame, NPMolly Davis, NPRaYoung Chung, NPRoxanne Griswold, NPRui Li, MD, PhDSasha Stanton, MD, PhDZheng Topp, MDRecruiting - Providence St. Vincent Medical Center
Portland, Oregon, United States
David Page, MDRecruiting - Swedish Cancer Institute
Seattle, Washington, United States
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Sept 2024
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2029
- Last update posted
- 15 Jan 2026
- Registered enrollment
- 12
- Registry id
- NCT06353997
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.